Skip to content
DataLookout
Menu

NCT07366086

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

StatusRecruiting
PhasePhase 3
SponsorAmgen
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words
    • Trial sites expanded: 4 → 9 locations
  2. Minor Primary and study completion moved earlier from May 21, 2028 to Apr 19, 2028v5
  3. Minor Study sites: 3 to 4v4
  4. Minor Study sites: 2 to 3v3
  5. Notable Recruitment opened
    • Study sites: 0 to 2
    • Start date changed from estimate of Mar 7, 2026 to Mar 18, 2026
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Adverse Events (AEs)
Timeframe: Up to 9 months

Arms and interventions

Standard of CareOther

Participants who completed romosozumab trial 20200105 will continue to receive standard of care treatment (calcium and vitamin D), as determined by the investigator and local guidance. No investigational drug product will be administered in this trial as this is a safety follow-up.

Dietary supplements: Vitamin D, Calcium

Sites

9 sites in 6 countries

United States 3, Germany 2, Belgium 1, China 1, Hungary 1, Japan 1